Picture of Biostem Technologies logo

BSEM Biostem Technologies Income Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapSuper Stock

Annual income statement for Biostem Technologies, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2017
December 31st
2020
December 31st
2021
December 31st
R2023
December 31st
2024
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:ARSARSARSPRESSPRESS
Standards:
USG
U
USG
U
USG
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue0.3292.524.3416.7302
Cost of Revenue
Gross Profit0.1791.252.8215.4288
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses5.164.365.1424.5271
Operating Profit-4.83-1.84-0.802-7.7831.2
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes-4.86-2.37-1.41-8.4830.6
Provision for Income Taxes
Net Income After Taxes-4.86-2.37-1.41-8.4831.9
Minority Interest
Net Income Before Extraordinary Items
Net Income-4.84-2.39-1.37-8.4831.9
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income-4.84-2.39-1.37-8.4831.9
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS-1.15-0.257-0.215-0.6171.47